BioXcel Therapeutics Inc (BioXcel Therapeutics) is a commercial-stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. The company pipeline product portfolio comprises BXCL501, an adrenergic agent with a sublingual route of administration used for treating neuropsychiatric and neurodegenerative diseases, BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers and BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders. BioXcel Therapeutics' drug re-innovation approach leverages existing approved drugs and clinically validated product candidates with big data and proprietary machine learning algorithms to develop new therapeutic candidates. BioXcel Therapeutics is headquartered in New Haven, Connecticut, the US.
Headquarters
United States of America
Address
555 Long Wharf Dr, New Haven, Connecticut, 06511-6107
Website
www.bioxceltherapeutics.com
Telephone
1 203 6438060
No of Employees
74
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BTAI (NASD)
Revenue (2022)
$1.4M
268%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-8%
(2022 vs 2021)
Market Cap*
$97.0M
Net Profit Margin (2022)
XYZ
70.7%
(2022 vs 2021)
* As of and is in US$
BioXcel Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline Products | KalmPenTM |
| BXCL501: | |
| Geriatric Dementia | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In November, the company announced its plans to raise up to US$150 million in public offering of common stock. |
| 2022 | Others | In December, the company announced that the first patient was dosed in the pivotal Phase 3 TRANQUILITY III trial of BXCL501 (dexmedetomidine) sublingual film. |
| 2022 | Financing Agreements | In April, the company secured an investment of US$5 million in private financing. |
Competitor Comparison
| Key Parameters | BioXcel Therapeutics Inc | Pieris Pharmaceuticals Inc | Proteome Sciences Plc | Biostax Corp | Eisai Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | United States of America |
| City | New Haven | Boston | Addlestone | Winter Park | Nutley |
| State/Province | Connecticut | Massachusetts | England | Florida | New Jersey |
| No. of Employees | 74 | 46 | 29 | - | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Mueller, Ph.D. | Chairman | Executive Board | 2017 | 67 |
| Vimal Mehta, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2017 | 62 |
| Richard I. Steinhart | Senior Vice President; Chief Financial Officer | Senior Management | 2018 | 66 |
| Javier Rodriguez | Senior Vice President; Secretary; Chief Legal Officer | Senior Management | 2021 | 51 |
| Frank D. Yocca, Ph.D | Senior Vice President; Chief Scientific Officer | Senior Management | 2017 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward